Inhibition of C1q-beta-amyloid binding protects hippocampal cells against complement mediated toxicity

J Neuroimmunol. 2003 Apr;137(1-2):12-8. doi: 10.1016/s0165-5728(03)00040-7.

Abstract

Activation of complement by beta-amyloid (A beta) contributes to the pathology of Alzheimer's disease (AD). Here, we show that C1-Inhibitor (C1-Inh) protects cultured rat hippocampal cells against beta-amyloid induced complement lysis indicating a classical pathway-mediated activation mechanism. We report on screening of compound libraries to identify compounds that inhibit C1q binding to beta-amyloid. Characterization of these compounds revealed that C1q possessed distinct binding sites for beta-amyloid and antibodies. One selected compound protected cultured hippocampal cells against complement-dependent beta-amyloid toxicity. These results provide evidence that complement has the potential to damage hippocampal cells, and C1q is a relevant target to suspend this deleterious mechanism in Alzheimer's disease.

MeSH terms

  • Amyloid beta-Peptides / antagonists & inhibitors*
  • Amyloid beta-Peptides / metabolism
  • Amyloid beta-Peptides / toxicity*
  • Animals
  • Binding Sites / drug effects
  • Binding Sites / immunology
  • Cells, Cultured
  • Complement C1q / antagonists & inhibitors*
  • Complement C1q / metabolism
  • Complement C1q / physiology*
  • Complement Pathway, Classical / drug effects
  • Complement Pathway, Classical / immunology
  • Hippocampus / cytology
  • Hippocampus / drug effects
  • Hippocampus / immunology*
  • Hippocampus / metabolism*
  • Humans
  • Peptide Fragments / antagonists & inhibitors*
  • Peptide Fragments / metabolism
  • Peptide Fragments / toxicity*
  • Protein Binding / drug effects
  • Protein Binding / immunology
  • Rats
  • Rats, Wistar

Substances

  • Amyloid beta-Peptides
  • Peptide Fragments
  • amyloid beta-protein (1-40)
  • Complement C1q